A Double-Blind Combination Study of Clonazepam with Sertraline in Obsessive-Compulsive Disorder

References

• Greist J, Jefferson J: Pharmacotherapy for obsessive-compulsive disorder. Br J Psychiatry 1998; 173\(suppl 35):65–70.
   Google Scholar
• Jenike MA: Drug treatment of obsessive-compulsive disorders. In: Jenike MA, Baer L, Minichiello WE, eds. Obsessive-Compulsive Disorders. Ed. 3. St Louis, Mo: Mosby: 1998:469–523.
   Google Scholar
• Pigott TA, Seay S: Pharmacotherapy of obsessive-compulsive disorder. Int Review Psychiatry 1997; 9:133–147.
   Google Scholar
• Grady T, Pigott TA, L'Heureux F, Hill J, Bernstein L, Murphy D: A double-blind study of adjuvant buspirone hydrochloride in fluoxetine-treated patients with OCD. Am J Psychiatry 1993; 150: 819–821.
   PubMed Web of Science ®Google Scholar
• Jenike M, Baer L, Buttolph L: Buspirone augmentation of fluoxetine in patients with OCD. J Clin Psychiatry 1991; 1:13–14.
   Google Scholar
• McDougle C, Price L, Goodman W, Charney D, Heninger G: A controlled trial of lithium augmenta-tion in fluvoxamine-refractory obsessive-compulsive disorder. J Clin Psychopharmacol 1991; 11:175–184.
   PubMed Web of Science ®Google Scholar
• Rasmussen S: Lithium and tryptophan augmentation in clomipramine-resistant OCD. Am J Psychiatry 1984; 141:1283–1285.
   PubMed Web of Science ®Google Scholar
• Koran LM, Ringold AL, Elliot MA: Olanzapine aug-mentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2000; 61(Suppl 7):514–517.
   Google Scholar
• Iwata I, Kotani Y, Hoshino R, Takei N, Iyo M, Mori N: Carbamazepine augmentation of clomipramine in the treatment of refractory obsessive-compulsive disorder [letter]. J Clin Psychiatry 2000; 61:528–529.
   PubMed Web of Science ®Google Scholar
• Cora-Locatelli G, Greenberg BD, Martin J, Murphy D: Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder [letter]. J Clin Psychiatry 1998; 59(Suppl 9):480–481.
   Google Scholar
• Fux M, Benjamin J, Belmaker RH: Inositol versus pla-cebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: A double-blind cross-over study. Int J Neuropsychophar-macol 1999; 2:193–195.
   PubMed Web of Science ®Google Scholar
• Hewlett WA, Vinogradov S, Agras WS: Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1992; 12:420–430.
   PubMed Web of Science ®Google Scholar
• Hewlett WA, Vinogradov S, Agras WS: Clonazepam treatment of obsessions and compulsions. J Clin Psy-chiatry 1990; 51:158–161.
   Google Scholar
• Bacher NM: Clonazepam treatment of obsessive com-pulsive disorder [letter]. J Clin Psychiatry 1990; 4:168–169.
   Google Scholar
• Bodkin, White K: Clonazepam in the treatment of obsessive-compulsive disorder associated with panic disorder in one patient. J Clin Psychiatry 1989; 50:265–266.
   Google Scholar
• Jenike MA, Rauch S: Managing the patient with treatment-resistant obsessive compulsive disorder: Current strategies. J Clin Psychiatry 1994; 55(Suppl 3):11–17.
   PubMedGoogle Scholar
• McDougle J: Update on pharmacologic management of OCD: Agents and augmentation. J Clin Psychiatry 1997; 58(Suppl 12):11–28.
   PubMedGoogle Scholar
• Piggot TA, et al. Controlled study of clonazepam augmentation in clomipramine- or fluoxetine-treated patients with OCD. New Research Abstracts of the 145th annual meeting of the American Psychiatric Association: May 20–24, 1992; Washington DC. Abstract NR44;82
   Google Scholar
• Hollander E, Kaplan A, Stahl S: A double-blind, pla-cebo-controlled trial of clonazepam in obsessive-compulsive disorder. World J Biol Psychiatry 2003; 4:30–34.
   PubMed Web of Science ®Google Scholar
• Stein DJ, Hollander E, Mullen LS, DeCaria CM, Liebowitz MR: Comparison of clomipramine, alpra-zolam, and placebo in the treatment of obsessive-compulsive disorder. Hum Psychopharmacol 1992; 7:389–395.
   Web of Science ®Google Scholar
• Hwang EC, Van Woert MH: Antimyoclonic action of clonazepam: The role of serotonin. Eur J Pharmacol 1979; 60:31–40.
   PubMedGoogle Scholar
• Pranzatelli M: Benzodiazepine-induced shaking behav-ior in the rat: Structure activity and relation to serotonin and benzodiazepine receptors. Exp Neurol 1989; 104:241–250.
   Google Scholar
• Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney D: Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 2001; 58:681–686.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association: Diagnostic and Stat-istical Manual of Mental Disorders, 4th edit Washington, DC: American Psychiatric Association; 1994.
   Google Scholar
• Sheehan DV, Lecrubier Y, Harnett-Sheehan K, Amorim P. Janavs J, Weiller E, Hergueta T, Baker R, Dunbar G: The Mini International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview. J Clin Psychiatry 1998; 59 (Suppl 20): 22–23.
   Google Scholar
• Insel R, Murphy D, Cohen R, Alterman I, Kilts C, Linnoila M: Obsessive-Compulsive disorder: A double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983; 40:605–612.
   PubMed Web of Science ®Google Scholar
• Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P. Heninger GR: The Yale-Brown Obsessive-Compulsive Scale, part 1: Development, use, and reli-ability. Arch Gen Psychiatry 1989; 46:1006–1016.
   Google Scholar
• Guy W (Ed.): Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology, US Depart-ment of Health, Education, and Welfare. Washington, DC: Publication ADM 76–338; 1976:219–222.
   Google Scholar
• Hamilton M: The Assessment of anxiety states by rating. Br J Med Psychol 1959; 32:10–16.
   Google Scholar
• Hamilton M: A Rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56–62.
   PubMed Web of Science ®Google Scholar
• Worthington, et al. The effectiveness and safety of com-bined therapy with paroxetine and clonazepam compared to paroxetine alone for panic: Interim analysis. Poster ses-sion presented at the New Clinical Drug Evaluation Unit Program 39th Annual Meeting: June 1–4, 1999; Boca Raton, Fla. Poster No.6.
   Google Scholar
• Smith WT, Londborg PD, Glaudin V, Painter JR: Extended low-dose clonazepam cotherapy of fluoxetine in the treatment of depressed outpatients. Int J Neuro-psychopharmacol 2000; 3(Suppl 1):5231.
   Google Scholar
• Johnson MR, Marazziti D, Brawman-Mintzer O, Emmanuel NP, Ware MR, Morton A, Rossi A, Cassano GB, Lydiard RB: Abnormal peripheral benzodiazepine receptor density associated with generalized social pho-bia. Biol Psychiatry 1998; 43(4):306–309.
   Google Scholar
• Davidson JR: Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2001; 62:46–50.
   PubMedGoogle Scholar
• Rickels R, Downing R, Schweizer E, Hassman H: Anti-depressants for the treatment of generalized anxiety dis-order. Arch Gen Psychiatry 1993; 50:884–894.
   PubMed Web of Science ®Google Scholar
• Rocca PF, Scotta M, Zanalda E, Ravizza L: Paroxetine efficacy in the treatment of generalized anxiety dis-order. Acta Psychiatr Scand 1997; 95:444–449.
   PubMed Web of Science ®Google Scholar
• Gelpin E, Bonne O, Pen T, Brandes D, Shaky AY: Treat-ment of recent trauma survivors with benzodiazepines: A prospective study. J Clin Psychiatry 1996; 57(9): 390–394.
   PubMed Web of Science ®Google Scholar
• Mellman TA, Byers PM, Augenstein JS: Pilot evalua-tion of hypnotic medication during acute traumatic stress response. J Traumatic Stress 1998; 11(3): 563–569.
   PubMed Web of Science ®Google Scholar
• Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney D: Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 2001; 58:681–686.
   PubMed Web of Science ®Google Scholar
• Diler RS, Avci A: SSRI-induced mania in obsessive compulsive disorder [letter]. J Am Acad Child Adolesc Psychiatry 1999; 38:6–7.
   Google Scholar
• Ackerman D, Greenland S, Bystritsky A: Side effects as predictors of drug response in obsessive compulsive disorder. J Clin Psychopharmacol 1999; 5:459–465.
   Google Scholar
• Greist JH, Jefferson JW, Kobak KA, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz MR, Lydiard B: A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychophar-macol 1995; 10(2):57–65.
   PubMed Web of Science ®Google Scholar